Abstract
Clozapine, an atypical antipsychotic, is a dibenzodiazepine derivative and its therapeutic effects are probably mediated by dopaminergic and serotonergic activity. In accordance to several studies, it appears to be the most effective antipsychotic drug for treatment-resistant schizophrenia. Moreover, clozapine appears to be particularly beneficial in patients with schizophrenia who are suicidal and in those with comorbid substance use disorder. However, despite its efficacy, the general use of clozapine in clinical practice is somewhat limited because of the risk of several serious adverse effects such as agranulocytosis and thromboembolism. Clozapine may be associated with fatal myocarditis and cardiomyopathy in physically healthy young adults. Consequently, the FDA and the drug's manufacturer have strengthened warnings to include that a potentially fatal myocarditis may occur when taking clozapine. In the present paper the literature on clozapine-related myocardis will be reviewed and practical advice will be given concerning the diagnosis and management of such potentially fatal adverse effect.
Keywords: Clozapine, myocarditis, cardiomyopathy schizophrenia, heart failure
Current Drug Safety
Title:Update on the Adverse Effects of Clozapine: Focus on Myocarditis
Volume: 7 Issue: 1
Author(s): Domenico De Berardis, Nicola Serroni, Daniela Campanella, Luigi Olivieri, Francesca Ferri, Alessandro Carano, Marilde Cavuto, Giovanni Martinotti, Alessandra Cicconetti, Monica Piersanti, Francesco Saverio Moschetta and Massimo Di Giannantonio
Affiliation:
Keywords: Clozapine, myocarditis, cardiomyopathy schizophrenia, heart failure
Abstract: Clozapine, an atypical antipsychotic, is a dibenzodiazepine derivative and its therapeutic effects are probably mediated by dopaminergic and serotonergic activity. In accordance to several studies, it appears to be the most effective antipsychotic drug for treatment-resistant schizophrenia. Moreover, clozapine appears to be particularly beneficial in patients with schizophrenia who are suicidal and in those with comorbid substance use disorder. However, despite its efficacy, the general use of clozapine in clinical practice is somewhat limited because of the risk of several serious adverse effects such as agranulocytosis and thromboembolism. Clozapine may be associated with fatal myocarditis and cardiomyopathy in physically healthy young adults. Consequently, the FDA and the drug's manufacturer have strengthened warnings to include that a potentially fatal myocarditis may occur when taking clozapine. In the present paper the literature on clozapine-related myocardis will be reviewed and practical advice will be given concerning the diagnosis and management of such potentially fatal adverse effect.
Export Options
About this article
Cite this article as:
De Berardis Domenico, Serroni Nicola, Campanella Daniela, Olivieri Luigi, Ferri Francesca, Carano Alessandro, Cavuto Marilde, Martinotti Giovanni, Cicconetti Alessandra, Piersanti Monica, Saverio Moschetta Francesco and Di Giannantonio Massimo, Update on the Adverse Effects of Clozapine: Focus on Myocarditis, Current Drug Safety 2012; 7 (1) . https://dx.doi.org/10.2174/157488612800492681
DOI https://dx.doi.org/10.2174/157488612800492681 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antimicrobial Drug Interactions in the Critically Ill Patients
Current Clinical Pharmacology Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease
Current Vascular Pharmacology NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
Current Medicinal Chemistry Calcium Related Genes in Dogs as Potential Cardiac Biomarkers for the Detection of Chronic Mitral Valve Disease
Recent Patents on Biomarkers Aetiology, Diagnosis and Treatment of Hydrops Foetalis
Current Pediatric Reviews Perinatal Heart Programming: Long-term Consequences
Current Medicinal Chemistry Selective Peroxisome Proliferator-Activated Receptor-γ Modulation to Reduce Cardiovascular Risk in Patients with Insulin Resistance
Recent Patents on Cardiovascular Drug Discovery The Two Faces of Iminoalditols: Powerful Inhibitors Trigger Glycosidase Activation
Current Enzyme Inhibition Novel Strategies for the Detection of Systolic and Diastolic Heart Failure
Current Cardiology Reviews Recent Advances and Patents on Coronary Sinus Perfusion Devices for Treatment of Heart Disease
Recent Patents on Biomedical Engineering (Discontinued) Cellular Mechanisms for Diastolic Dysfunction in the Human Heart
Current Pharmaceutical Biotechnology Ibubrofen in the Treatment of Patent Ductus Arteriosus in Preterm Infants: What We Know, What We Still Do Not Know
Current Pharmaceutical Design Parasite Polyamines as Pharmaceutical Targets
Current Pharmaceutical Design Cardiac Amyloidosis Responding to Bortezomib: Case Report and Review of Literature
Current Cardiology Reviews Cardiac Amyloid - A Hidden Contributor to Cardiac Dysfunction Following Cardiac Surgery: Case Report and Literature Review
Current Cardiology Reviews The Effects of Vitamin B in Depression
Current Medicinal Chemistry Iatrogenic Right Atrial Thrombus Complicated by Pulmonary Embolism: Management and Outcomes
Current Cardiology Reviews A Review of Maternal and Fetal Growth Factors in Diabetic Pregnancy
Current Diabetes Reviews Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy Low Dose Chest Computed Tomography, in Identifying Pulmonary Complications in Immunocompromised Patients After Allogeneic Hematopoietic Stem Cell Transplantation
Current Respiratory Medicine Reviews